https://www.selleckchem.com/
01). CONCLUSION Our study shows that 9.7% of the eyes with ME secondary to DR and RVO developed a rebound phenomenon following IVTA injection, limiting its therapeutic effect. We found an increased number of prior intravitreal pharmacotherapy to be a risk factor for a rebound phenomenon. © 2020 S. Karger AG, Basel.INTRODUCTION The aim of this study is to assess and compare the long-term clinical efficacy of anti-VEGF drugs through the I-Maculaweb registry. METHODS Observational study based on the I-Maculaweb registry. Outcomes measures were the number of in
Synes godt om
Kommentar
Del
